ESLA Q2 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$291,513

Free Cash Flow

-$291,510

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4M

Total Liabilities

$180,701

Stockholders' Equity

$4M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$169,240	-2233.6%
Net Income	-$4M	-$76,004	-5098.5%